TY - JOUR T1 - DRUL for School: Opening Pre-K with safe, simple, sensitive saliva testing for SARS-CoV-2 JF - medRxiv DO - 10.1101/2021.04.03.21254873 SP - 2021.04.03.21254873 AU - Mayu O. Frank AU - Nathalie E. Blachere AU - Salina Parveen AU - Ezgi Hacisuleyman AU - John Fak AU - Joseph M. Luna AU - Eleftherios Michailidis AU - Samara Wright AU - Pamela Stark AU - Ann Campbell AU - Ashley Foo AU - Thomas P. Sakmar AU - Virginia Huffman AU - Marissa Bergh AU - Audrey Goldfarb AU - Andres Mansisidor AU - Agata L. Patriotis AU - Karl H. Palmquist AU - Nicolas Poulton AU - Rachel Leicher AU - César D. M. Vargas AU - Irene Duba AU - Arlene Hurley AU - Joseph Colagreco AU - Nicole Pagane AU - Dana E. Orange AU - Kevin Mora AU - Jennifer L. Rakeman AU - Randall C. Fowler AU - Helen Fernandes AU - Michelle F. Lamendola-Essel AU - Nick Didkovsky AU - Leopolda Silvera AU - Joseph Masci AU - Machelle Allen AU - Charles M. Rice AU - Robert B. Darnell Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/04/06/2021.04.03.21254873.abstract N2 - To address the need for simple, safe, sensitive, and scalable SARS-CoV-2 tests, we validated and implemented a PCR test that uses a saliva collection kit use at home. Individuals self-collected 300 µl saliva in vials containing Darnell Rockefeller University Laboratory (DRUL) buffer and extracted RNA was assayed by RT-PCR (the DRUL saliva assay). The limit of detection was confirmed to be 1 viral copy/µl in 20 of 20 replicate extractions. Viral RNA was stable in DRUL buffer at room temperature up to seven days after sample collection, and safety studies demonstrated that DRUL buffer immediately inactivated virus at concentrations up to 2.75×106 PFU/ml. Results from SARS-CoV-2 positive nasopharyngeal (NP) swab samples collected in viral transport media and assayed with a standard FDA Emergency Use Authorization (EUA) test were highly correlated with samples placed in DRUL buffer. Direct comparison of results from 162 individuals tested by FDA EUA oropharyngeal (OP) or NP swabs with co-collected saliva samples identified four otherwise unidentified positive cases in DRUL buffer. Over six months, we collected 3,724 samples from individuals ranging from 3 months to 92 years of age. This included collecting weekly samples over 10 weeks from teachers, children, and parents from a pre-school program, which allowed its safe reopening while at-risk pods were quarantined. In sum, we validated a simple, sensitive, stable, and safe PCR-based test using a self-collected saliva sample as a valuable tool for clinical diagnosis and screening at workplaces and schools.Competing Interest StatementR.B.D. wishes to disclose that he receives consulting fees as a Senior Visiting Fellow at MITRE Corporation, has started a charitable LLC, D4S Testing, to offer free DRUL saliva testing to NYC school children, and is an Investigator of the Howard Hughes Medical Institute.Funding StatementC.M.R acknowledges the generous support of the G. Harold and Leila Y. Mathers Charitable Foundation, the BAWD Foundation, and The Rockefeller University. R.B.D. is an Investigator of the Howard Hughes Medical Institute.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Protocols for the collection of saliva samples were either approved by the Rockefeller University (RU) Institutional Review Board (IRB) and Biomedical Research Alliance of New York IRB or were deemed not to be human subjects research by the RU IRB. Where required, written or verbal consent was obtained from all volunteers.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll raw data in this manuscript is available upon request. ER -